Ken Griffin Pds Biotechnology Corp Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$3.85 - $6.59 $599,445 - $1.03 Million	-155,700 Reduced 93.46%	10,900 $43,000
Q4 2023 Feb 14, 2024	BUY	$3.95 - $6.58 $130,350 - $217,140	33,000 Added 24.7%	166,600 $828,000
Q3 2023 Nov 14, 2023	BUY	$4.8 - $6.4 $27,360 - $36,480	5,700 Added 4.46%	133,600 $674,000
Q2 2023 Aug 14, 2023	SELL	$5.03 - $9.9 $281,680 - $554,400	-56,000 Reduced 30.45%	127,900 $643,000
Q1 2023 May 15, 2023	SELL	$5.68 - $11.99 $1.25 Million - $2.63 Million	-219,500 Reduced 54.41%	183,900 $1.13 Million

Q4 2022 Feb 14, 2023	BUY	$4.92 - $13.2 $235,176 - $630,960	47,800 Added 13.44%	403,400 $5.32 Million
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.79 $179,664 - $342,189	-59,100 Reduced 14.25%	355,600 $1.06 Million

7.53M

140K

318K

Ticker PDSB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,458,700
Market Cap $91.9M
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.